Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

795 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019.
Ugurel S, Röhmel J, Ascierto PA, Becker JC, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Livingstone E, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Zimmer L, Schadendorf D, Garbe C. Ugurel S, et al. Among authors: garbe c. Eur J Cancer. 2020 May;130:126-138. doi: 10.1016/j.ejca.2020.02.021. Epub 2020 Mar 13. Eur J Cancer. 2020. PMID: 32179447
Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group.
Kaufmann R, Spieth K, Leiter U, Mauch C, von den Driesch P, Vogt T, Linse R, Tilgen W, Schadendorf D, Becker JC, Sebastian G, Krengel S, Kretschmer L, Garbe C, Dummer R; Dermatologic Cooperative Oncology Group. Kaufmann R, et al. Among authors: garbe c. J Clin Oncol. 2005 Dec 10;23(35):9001-7. doi: 10.1200/JCO.2005.01.1551. Epub 2005 Oct 31. J Clin Oncol. 2005. PMID: 16260697 Clinical Trial.
Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma.
Müller-Horvat C, Radny P, Eigentler TK, Schäfer J, Pfannenberg C, Horger M, Khorchidi S, Nägele T, Garbe C, Claussen CD, Schlemmer HP. Müller-Horvat C, et al. Among authors: garbe c. Eur J Cancer. 2006 Feb;42(3):342-50. doi: 10.1016/j.ejca.2005.10.008. Epub 2005 Dec 20. Eur J Cancer. 2006. PMID: 16364631
[Brief guidelines: malignant melanoma of the skin].
Garbe C, Hauschild A, Volkenandt M, Schadendorf D, Stolz W, Kortmann RD, Kettelhack C, Frerich B, Keilholz U, Dummer R, Sebastian G, Tilgen W, Schuler G, Mackensen A, Kaufmann R. Garbe C, et al. J Dtsch Dermatol Ges. 2006 Apr;4(4):344-9. doi: 10.1111/j.1610-0387.2006.05891.x. J Dtsch Dermatol Ges. 2006. PMID: 16638065 Review. German. No abstract available.
[Melanocytic nevi].
Hauschild A, Garbe C, Bauer J, Hamm H, Kerl H, Reusch M, Rompel R, Schlaeger M; weitere Mitglieder der Expertengruppe "melanozytäre Nävi". Hauschild A, et al. Among authors: garbe c. J Dtsch Dermatol Ges. 2006 Aug;4(8):686-97. doi: 10.1111/j.1610-0387.2006.05865.x. J Dtsch Dermatol Ges. 2006. PMID: 16895572 German. No abstract available.
Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma.
Pfannenberg C, Aschoff P, Schanz S, Eschmann SM, Plathow C, Eigentler TK, Garbe C, Brechtel K, Vonthein R, Bares R, Claussen CD, Schlemmer HP. Pfannenberg C, et al. Among authors: garbe c. Eur J Cancer. 2007 Feb;43(3):557-64. doi: 10.1016/j.ejca.2006.11.014. Epub 2007 Jan 16. Eur J Cancer. 2007. PMID: 17224266
795 results